Roivant Sciences (ROIV) is experiencing a notable build in bearish positioning, with short interest reaching 5.7% of the free float as of November 5, 2026. This marks the highest level of short interest for the company in at least 12 months. The increase follows a step-change in early October when short positions rose from approximately 36 million shares. While borrowing costs remain relatively low at 0.42%, the consistent accumulation of short positions suggests institutional skepticism. Additionally, the company has seen significant insider selling, with $43.9 million in net sales over the last 90 days, further complicating the bullish narrative.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.